Sana lays off staff as cell therapy biotech awaits first clinical data
Cell therapy maker Sana Biotechnology is laying off staff, based on about half a dozen employee posts on LinkedIn in recent days.
Sana expects its first clinical data later this year — a key test of whether its so-called hypoimmune technology works at preventing the rejection of allogeneic cells, or those not originating from the patient. Autologous, or self-derived, cell therapies have been on the market for about five years, but the allogeneic approach has lingered behind due to various immune system complexities.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.